Most practices are not ready to transition to the Medicare Access and CHIP Reauthorization Act (MACRA) payment models, although there is a leading group of practices that are more prepared to make the switch, said Aaron Lyss, director of value-based care for Tennessee Oncology.
Most practices are not ready to transition to the Medicare Access and CHIP Reauthorization Act (MACRA) payment models, although there is a leading group of practices that are more prepared to make the switch, said Aaron Lyss, director of value-based care for Tennessee Oncology.
Transcript (slightly modified)
Are practices ready for the transition to MACRA? Do they understand it, MIPS, APMs, and how the Oncology Care Model fits in?
I’ll give you a short answer—that’s no, I don’t think they are ready. That just speaks to what I see among oncology practices nationwide.
Having said that, there are a leading group of practices on that curve that are much more prepared for what’s happening in this space than others and I think we’re in that cohort of practices that are as ready as any for these types of changes. But, I do think it’s a problem nationwide that a lot of practices just haven’t had the foresight to build the infrastructure and data management capabilities over the past several years. So, they haven’t had the foresight to start several years ago down this road, so they can be in a position to be ready in the near term.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More